Finch

Finch Therapeutics Announces $90 Million Financing to Advance Pipeline of Investigational Oral Microbiome Drugs

Proceeds to support the advancement of lead candidate through the final stages of clinical development for recurrent C. difficile infection, and the advancement into the clinic of programs for autism spectrum disorder and chronic hepatitis B Somerville, MA, September 17, 2020 – Finch Therapeutics Group, Inc. (“Finch”), a clinical-stage microbiome drug development company, announced today[…]

Finch

Finch Therapeutics Announces Positive Topline Results from Randomized Controlled Trial of CP101, an Oral Microbiome Drug, for the Prevention of Recurrent C. difficile Infection

CP101 met the primary efficacy endpoint with statistically significant improvement in the prevention of recurrent C. difficile infection over standard of care alone in a 206-patient trial CP101 was well-tolerated with no treatment-related serious adverse events CP101 is the first oral microbiome drug to meet its primary endpoint in a pivotal trial Finch announces the[…]

Finch

Finch Therapeutics’ Investigational Drug CP101 Granted Breakthrough Therapy Designation from FDA for Recurrent C. Difficile Infection

February 8, 2019 TPTF invest in Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, in Series B-1 funding. Currently, Finch is actively enrolling patients with recurrent Clostridium difficile (C. difficile) infection Phase II clinical study to assess the safety and efficacy of an investigational drug CP101. The study drug is an oral capsule that is administered in a single dose.